RAS基因突变与结直肠癌发生发展及靶向治疗相关性的研究进展

olorectal cancer (CRC) is the third most common cancer in the world. RAS gene (mainly in KRAS and NRAS genes) mutations played an important role in the development of CRC. The presence of mutations in RAS was predictive for a lack of response to treatments with monoclonal antibodies against the epidermal growth factor receptor (EGFR) in patients, and was closely related to patients' clinical and pathological features and survival. Identify the molecular mechanisms of RAS mutations in CRC development and assess the predictive or prognostic value of RAS were of great importance. However, current researches focused on different types of RAS mutations have not reached a unified conclusion. Therefore, we review studies on RAS mutations as predictive or prognostic markers for CRC patients.